1.EIF5A2 Expression in Hepatocellular Carcinoma and Its Relation with Postoperative Survival
Qian YANG ; Dongxue YE ; Yanran MA ; Xiaoyuan HU ; Hong LI ; Xuan ZHOU ; Fenggang XIANG
Cancer Research on Prevention and Treatment 2021;48(6):617-624
Objective To detect the expression of EIF5A2 in hepatocellular carcinoma(HCC) and to explore its relation with clinicopathological characters and prognosis of HCC patients. Methods The expression of EIF5A2 mRNA and protein in 12 pairs of fresh HCC and corresponding non-tumor tissues adjacent to the cancer was examined by qRT-PCR and Western blot. The expression level of EIF5A2 in 284 pairs of HCC and adjacent non-tumor tissues was detected by IHC staining. Then we analyzed between EIF5A2 expression and clinical pathological parameters and prognosis of HCC patients. Results The relative expression levels of EIF5A2 mRNA and protein in fresh HCC tissues were significantly higher than those in the corresponding adjacent non-tumor tissues (
2.Research progress of fibroblast growth factor in nervous system diseases.
Wenting HUANG ; Wanhua QIU ; Kun CHEN ; Shasha YE ; Dongxue WANG ; Jian HU ; Huiqin XU ; Li LIN ; Xiaokun LI
Journal of Zhejiang University. Medical sciences 2023;51(6):738-749
Fibroblast growth factors (FGF) are a group of structurally related polypeptides which constitute an elaborate signaling system with their receptors. Evidence accumulated in the years suggests that the FGF family plays a key role in the repair of central nervous system injury. The main protective mechanisms include activating the expression of PI3K-Akt, peroxisome proliferator-activated receptor (PPARγ) and other signals; inhibiting NF-κB-mediated inflammatory response, oxidative stress and apoptosis; regulating neuronal differentiation and neuronal excitability as well as participating in protection of neurovascular units and nerve function repair. This paper comprehensively summarizes the latest research progress in FGF signaling related to diseases of the central nervous system such as cerebral infarction, cerebral hemorrhage, traumatic brain injury, Alzheimer's disease, Parkinson's disease, epilepsy and depression, aiming to provide scientific basis and reference for the development of innovative FGF drugs for the prevention and treatment of neurological diseases.
Humans
;
Fibroblast Growth Factors
;
Phosphatidylinositol 3-Kinases/metabolism*
;
Central Nervous System/metabolism*
;
Signal Transduction/physiology*
;
Alzheimer Disease